Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization

Leukemia. 2008 Nov;22(11):2131-4. doi: 10.1038/leu.2008.167. Epub 2008 Jul 3.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Bone Marrow / drug effects*
  • Cell Movement / drug effects*
  • Cell Survival / drug effects
  • Cells, Cultured
  • Colony-Forming Units Assay
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / metabolism
  • Hematopoietic Stem Cells / cytology
  • Hematopoietic Stem Cells / drug effects*
  • Humans
  • Mesenchymal Stem Cells / cytology
  • Mesenchymal Stem Cells / drug effects*
  • Stromal Cells / drug effects
  • Vidarabine / analogs & derivatives*
  • Vidarabine / pharmacology

Substances

  • Antineoplastic Agents
  • Vidarabine
  • fludarabine